knowledge -WSS

knowledge

author：Wikipedia 2025-10-01 04:33:06 - browse：88862

The back of three medicine containers, a bottle in between two boxes, all showing labels — coverage from STAT — Adobe

After a drug enters the market, it’s up to Food and Drug Administration regulators to ensure its continued safety and efficacy. A recent New York Times story suggests that, in the case of the popular asthma drug Singulair, the FDA fell short — both because the agency delayed action for years on reports from patient advocates and independent groups that the drug could cause suicidal thoughts, and because when it did add a warning label about its potential side effects in 2020, clinicians and patients still weren’t always aware of the risks.

Experts say that the Singulair incident highlights a flawed system, both in the U.S. and globally, for monitoring adverse reactions after a drug is on the market — one that will require extensive changes to address.

“The question is, how safe do you want to be?” said Ameet Sarpatwari, the assistant director of the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital. Ideally, he said, the FDA should be able to both stay on top of safety concerns and avoid unnecessarily restricting access to drugs. “Are we at the right balance? I think there are definitely situations for many drugs where you can say, no, we’re not really at the right balance, and the FDA should be taking a more aggressive stance in promoting patient safety.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： How to fix the rural physician shortage in the U.S.

WSS

Biotech companies concerned about China biosecurity crackdown

A $475,000 price tag for a new cancer drug: crazy or meh?

Clinical trials giant ICON acquires HumanFirst

Time to name cancers by genetics, not organ of origin, expert says

Woodcock on FDA’s accelerated approval and her next chapter

RaDonda Vaught to speak at CommonSpirit event on patient safety

hotspot

knowledge

focus

23andMe had bad news about my health. I wish a person had delivered it

Quicker fix for pulse oximeters urged during FDA public meeting

Affirmative action in medical school literally saved lives

Why getting cancer drugs just got harder for rural patients

What does generative AI mean for health care? We asked experts

In search for therapies for solid tumors, companies turn to claudin

George Santos makes 1st court appearance after pleading not guilty to 13 counts

In search for therapies for solid tumors, companies turn to claudin

What does generative AI mean for health care? We asked experts

ALS groups 'won't be played again' by the FDA, drug sponsors

leisure time

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Congressmen charge Covid hearing ‘could have been an email’

FogPharma raises $145 million in rare Series E round

Commercial surrogacy can be ethical, despite pope’s claims

Readout Newsletter: Vertex, Biogen's Aduhelm, and Bristol updates

Kenai launches with $82 million for Parkinson’s stem cell therapy

Wikipedia

hotspot

hotspot

knowledge